HC Wainwright Has Negative Outlook for SPTX FY2026 Earnings

Key Points

• HC Wainwright cut Seaport Therapeutics’ FY2026 EPS estimate to a loss of $4.09 per share from its previous estimate of $3.25, while maintaining a “Buy” rating and $50 price target.
• Seaport reported a quarterly loss of $1.78 per share, missing analysts’ consensus estimate of a $0.71 loss by $1.07.
• Analyst sentiment is mixed: the stock has a consensus “Hold” rating and $38.40 average price target, despite five Buy ratings, three Holds and one Sell rating.

Seaport Therapeutics, Inc. (NASDAQ:SPTX - Free Report) - HC Wainwright lowered their FY2026 earnings per share estimates for Seaport Therapeutics in a research report issued on Tuesday, August 4th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($4.09) for the year, down from their prior estimate of ($3.25). HC Wainwright has a "Buy" rating and a $50.00 price objective on the stock. HC Wainwright also issued estimates for Seaport Therapeutics' Q1 2027 earnings at ($0.62) EPS, Q3 2027 earnings at ($0.67) EPS and FY2027 earnings at ($2.62) EPS.

Several other analysts have also recently commented on the company. Leerink Partners began coverage on Seaport Therapeutics in a research report on Tuesday, May 26th. They issued an "outperform" rating and a $35.00 target price on the stock. Seaport Research Partners set a $50.00 price target on Seaport Therapeutics in a research report on Wednesday, July 15th. JPMorgan Chase & Co. initiated coverage on Seaport Therapeutics in a research note on Tuesday, May 26th. They issued an "overweight" rating and a $42.00 price target for the company. UBS Group lowered Seaport Therapeutics to a "sell" rating in a report on Tuesday, June 9th. Finally, BNP Paribas Exane downgraded shares of Seaport Therapeutics to a "market perform" rating in a report on Tuesday, May 26th. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $38.40.

Seaport Therapeutics Stock Performance

Shares of NASDAQ:SPTX opened at $22.34 on Thursday. The firm has a 50-day moving average price of $19.52. The company has a market cap of $1.20 billion and a P/E ratio of -2.16. Seaport Therapeutics has a fifty-two week low of $14.85 and a fifty-two week high of $23.00.

Seaport Therapeutics (NASDAQ:SPTX - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($1.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($1.07).

Insider Activity

In related news, Director Robert J. Hombach acquired 13,000 shares of the business's stock in a transaction dated Monday, June 22nd. The stock was bought at an average price of $18.14 per share, for a total transaction of $235,820.00. Following the transaction, the director owned 13,000 shares of the company's stock, valued at approximately $235,820. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Seaport Therapeutics, Inc is a healthcare company in the Pharmaceuticals industry.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source